Premium
Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease
Author(s) -
Leenders Klaus L.
Publication year - 2003
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.10577
Subject(s) - parkinson's disease , neuroscience , dopaminergic , dopamine , context (archaeology) , neurotransmitter , tropane , single photon emission computed tomography , psychology , in vivo , dopamine receptor d2 , basal ganglia , positron emission tomography , nuclear medicine , medicine , pathology , central nervous system , disease , biology , paleontology , microbiology and biotechnology
Tropane‐related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D 2 receptors and HMPAO uptake is a measure of cerebral tissue perfusion. © 2003 Movement Disorder Society